Skip to main content
Clinical Trials/NCT00798382
NCT00798382CompletedPhase 2

Comparative Gastrointestinal Tolerance of Various Infant Formulas in Healthy Term Infants

Abbott Nutrition34 sites in 1 country154 target enrollmentStarted: December 2008Last updated:
Conditions

Trial Snapshot

Phase
Phase 2
Status
Completed
Enrollment
154
Locations
34
Primary Endpoint
Gastrointestinal tolerance from Study Visit 1 to Study Visit 3 at 35 days of age.

Study Overview

Brief Summary

The objective of this study is to assess the comparative gastrointestinal (GI) tolerance of normal term infants to two experimental soy-based formulas, relative to a commercially available soy-based formula.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

Eligibility Criteria

Ages
— to 8 Days (Child)
Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • Infant is judged to be in good health.
  • Infant is a singleton from a full term birth with a gestational age of 37-42 weeks.
  • Infant's birth weight was > 2490 g (~5 lb 8 oz).
  • Infant is between 0 and 8 days of age at enrollment.
  • Parent(s) confirm their intention to feed their infant the study product as the sole source of nutrition for the duration of the study.
  • Parent(s) confirm their intention not to administer vitamin or mineral supplements, solid foods or juices to their infant for the duration of the study.
  • Infants using medications or home remedies, herbal preparations or rehydration/intravenous (IV) fluids that might affect GI tolerance may not be enrolled.

Exclusion Criteria

  • An adverse maternal, fetal or infant medical history that is thought by the investigator to have potential for effects on tolerance, growth, and/or development.
  • Infant has been treated with antibiotics.
  • Infant has received probiotics.

Outcomes

Primary Outcomes

Gastrointestinal tolerance from Study Visit 1 to Study Visit 3 at 35 days of age.

Time Frame: 35 days

Secondary Outcomes

  • Additional gastrointestinal measures of tolerance from Study Visit 1 to Study Visit 3 at 35 days of age(35 days)

Investigators

Sponsor Class
Industry
Responsible Party
Sponsor

Study Sites (34)

Loading locations...

Similar Trials